Developments in pharmacotherapy for tobacco dependence: past, present and future

References

• Wayne G F, Connolly G M, Henningfield J E. Assessing internal tobacco industry knowledge of the neurobiology of tobacco dependence. Nicotine Tob Res 2004; 6: 927–940
   PubMedGoogle Scholar
• Foulds J, Burke M, Steinberg M, Williams J, Ziedonis D. Advances in pharmacotherapy for tobacco dependence. Exp Opin Emerg Drugs 2004; 9: 39–53
   PubMedGoogle Scholar
• Johnston L M. Tobacco smoking and nicotine. Lancet 1942; 2: 742
   Google Scholar
• Doll R, Hill A B. Smoking and carcinoma of the lung. Preliminary report. BMJ 1950; 2: 739–748
   PubMed Web of Science ®Google Scholar
• Wynder E L, Graham E A. Tobacco smoking as a possible etiologic factor in bronchogenic carcinoma. JAMA 1950; 143: 329–336
   PubMed Web of Science ®Google Scholar
• Herxheimer A, Griffiths R L, Hamilton B, Wake M. Circulatory effects of nicotine aerosol inhamations and cigarette smoking in man. Lancet 1967; ii: 754–755
   Google Scholar
• Ferno O. Converation with Ove Ferno. Addiction 1994; 89: 1215–1226
   PubMed Web of Science ®Google Scholar
• Jarvik M. Conversation with Murray Jarvik. Addiction 2001; 96: 1241–1252
   PubMedGoogle Scholar
• Russell M A. Conversation with Michael A.H. Russell. Addiction 2004; 99: 9–19
   PubMedGoogle Scholar
• Ferno O. A substitute for tobacco smoking. Psychopharmacologia 1973; 31: 201–204
   PubMed Web of Science ®Google Scholar
• Jarvis M J, Raw M, Russell M A, Feyerabend C. Randomised controlled trial of nicotine chewing-gum. Br Med J 1982; 285: 537–540
   PubMed Web of Science ®Google Scholar
• Hughes J R, Hatsukami D K, Pickens R W, Krahn D, Malin S, Luknic A. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 1984; 83: 82–87
   PubMed Web of Science ®Google Scholar
• Gross J, Stitzer M L. Nicotine replacement: ten-week effects on tobacco withdrawal symptoms. Psychopharmacology 1989; 98: 334–341
   PubMedGoogle Scholar
• Jarvis M J, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y. Comparison of tests used to distinguish smokers from nonsmokers. Am J Public Health 1987; 77: 1435–1438
   PubMed Web of Science ®Google Scholar
• Waage H, Silsand T, Urdal P, Langard D. Discrimination of smoking status by thiocyanate and cotinine in serum, and carbon monoxide in expired air. Int J Epidemiol 1992; 21: 488–493
   PubMed Web of Science ®Google Scholar
• Pojer R, Whitfield J W, Poulos V, Eckhardt I, Richmond R L, Hensley W J. Carboxyhaemoglobin, cotinine and thyocyanate assay compared for distinguishing smokers from non-smokers. Clin Chem 1984; 30: 1377–1380
   PubMed Web of Science ®Google Scholar
• SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002; 4: 149–159
   PubMedGoogle Scholar
• Dale L C, Hurt R D, Offord K P, Lawson G M, Croghan I T, Schroeder D R. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA 1995; 274: 1353–1358
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. The Health Consequences of Smoking: Nicotine Addiction. US Government Printing Office, Washington, DC 1988
   Google Scholar
• Abelin T, Buehler A, Muller P, Vesanen K, Imhof P R. Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet 1989; 1: 7–10
   PubMed Web of Science ®Google Scholar
• Sutherland G, Stapleton J A, Russell M A, et al. Randomized controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324–329
   PubMed Web of Science ®Google Scholar
• Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993; 269: 1268–1271
   PubMed Web of Science ®Google Scholar
• Wallstrom M, Nilsson F, Hirsch J M. A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. Addiction 2000; 95: 1161–1171
   PubMed Web of Science ®Google Scholar
• Foulds J. Does nicotine replacement therapy work?. Addiction 1993; 88: 1473–1478
   PubMed Web of Science ®Google Scholar
• Fiore M C, Bailey W C, Cohen S J, et al. Treating tobacco use and dependence: Clinical Practice Guideline. US Department of Health and Human Services, Public Health Service, Rockville, MD 2000
   Google Scholar
• Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004, issue 3: CD000146
   Google Scholar
• Foulds J, Stapleton J, Hayward M, et al. Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital: a placebo-controlled trial. Arch Fam Med 1993; 2: 417–423
   PubMedGoogle Scholar
• Richmond R, Harris K, de Aleido Neto A. The nicotine transdermal patch: results of a randomized placebo-controlled trial. Med J Aust 1994; 161: 130–135
   PubMed Web of Science ®Google Scholar
• Hughes J R, Gust S W, Keenan R M, Fenwick J W, Healey M L. Nicotine vs placebo gum in general medical practice. JAMA 1989; 261: 1300–1305
   PubMed Web of Science ®Google Scholar
• Davidson M, Epstein M, Burt R, Schaefer C, Whitworth G, McDonald A. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. Arch Fam Med 1998; 7: 569–574
   PubMedGoogle Scholar
• Hughes J R, Shiffmann S, Callas P, Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 2003; 12: 21–27
   PubMed Web of Science ®Google Scholar
• Research Subcommittee of the British Thoracic Society. Comparison of four methods of smoking withdrawal in patients with smoking related disease. BMJ 1983; 286: 595–597
   PubMedGoogle Scholar
• Stapleton J A, Russell M A, Feyerabend C. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 1995; 90: 31–42
   PubMed Web of Science ®Google Scholar
• Yudkin P L, Jones L, Lancaster T, Fowler G H. Which smokers are helped to give up smoking using transdermal nicotine patches: results from a randomized, double-blind, placebo-controlled trial. Br J Gen Pract 1996; 46: 145–148
   PubMed Web of Science ®Google Scholar
• Pierce J P, Gilpin E A. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002; 288: 1260–1264
   PubMed Web of Science ®Google Scholar
• Stead L F, Davis R M, Fiore M C, Hatsukami D K, Raw M, West R. Effectiveness of over-the-counter nicotine replacement therapy. JAMA 2002; 288: 3109–3110
   PubMed Web of Science ®Google Scholar
• Foulds J, Ramstrom L, Burke M, Fagerstrom K. The effect of smokeless tobacco (snus) on public health in Sweden. Tob Control 2003; 12: 349–359
   PubMed Web of Science ®Google Scholar
• Delnevo C, Hrywna M, Foulds J, Steinberg M B. Cigar use after a cigarette excise tax increase in New Jersey. Addict Behav 2004; 29: 1799–1807
   PubMed Web of Science ®Google Scholar
• Ferry L H. Non-nicotine pharmacotherapy for smoking cessation. Prim Care 1999; 26: 653–669
   PubMedGoogle Scholar
• McEvoy J P, Freudenreich O, Wilson W. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 46: 125–129
   PubMed Web of Science ®Google Scholar
• McEvoy J, Freudenreich O, McGee M, VanderZwaag C, Levin E, Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995; 37: 550–552
   PubMed Web of Science ®Google Scholar
• George T P, Ziedonis D M, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000; 157: 1835–1842
   PubMed Web of Science ®Google Scholar
• George T P, Sernyak M J, Ziedonis D M, et al. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56: 344–346
   PubMed Web of Science ®Google Scholar
• Jorenby D E, Leischow S J, Nides M A, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Eng J Med 1999; 340: 685–691
   PubMed Web of Science ®Google Scholar
• Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004, issue 4: CD00031
   Google Scholar
• Gourlay S B, Stead L F, Benowitz N L. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004, issue 3: CD00058
   Google Scholar
• Hughes J R, Stead L F, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst Rev 2000, issue 4: CD002849
   Google Scholar
• Jarvik M E, Caskey N J, Wirshing W C. Bromocriptine reduces cigarette smoking. Addiction 2000; 95: 1173–1183
   PubMed Web of Science ®Google Scholar
• West R. Glucose for smoking cessation: does it have a role?. CNS Drugs 2001; 15: 261–265
   PubMed Web of Science ®Google Scholar
• Berlin I, Said S, Spreux-Varoquaux O, et al. A reversible monoamine oxidase a inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 58: 444–452
   PubMed Web of Science ®Google Scholar
• Shytle R D, Penny E, Silver A A, Goldman J, Sanberg P R. Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens 2002; 16: 453–457
   PubMed Web of Science ®Google Scholar
• David S, Lancaster T, Stead L F. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 2001, issue 3: CD003086
   Google Scholar
• Rauhut A S, Mullins S N, Dwoskin L P, Bardo M T. Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther 2002; 303: 664–672
   PubMed Web of Science ®Google Scholar
• Anthenelli R M, Despres J P. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (Smoking Cessation in Smokers Motivated to Quit). Presented at the American College of Cardiology 53rd Annual Scientific Session. 9 March, 2004
   Google Scholar
• Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 2003; 98: 1403–1407
   PubMed Web of Science ®Google Scholar
• Oncken C. Efficacy and safety of varenicline for smoking cessation. Paper presented at National Conference on Tobacco or Health. Chicago May, 2005
   Google Scholar
• Slemmer J E, Martin B R, Damaj M I. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321–327
   PubMed Web of Science ®Google Scholar
• Fryer J D, Lukas R J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999; 288: 88–92
   PubMed Web of Science ®Google Scholar
• Prochazka A V, Kick S, Steinbrunn C, Miyoshi T, Fryer G E. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004; 164: 2229–2233
   PubMedGoogle Scholar
• Hall S M, Humfleet G L, Reus V I, Munoz R F, Cullen J. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry 2004; 161: 2100–2107
   PubMed Web of Science ®Google Scholar
• Miller D K, Wong E H, Chesnut M D, Dwoskin L P. Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther 2002; 302: 687–695
   PubMed Web of Science ®Google Scholar
• Klimek V, Zhu M Y, Dilley G, et al. Effects of long-term cigarette smoking on the human locus coeruleus. Arch Gen Psychiatry 2001; 58: 821–827
   PubMed Web of Science ®Google Scholar
• Page M E. The promises and pitfalls of reboxetine. CNS Drug Rev 2003; 9: 327–342
   PubMedGoogle Scholar
• George T P, Vessicchio J C, Termine A. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 2003; 53: 136–143
   PubMed Web of Science ®Google Scholar
• Hurt R D, Ahlskog J E, Croghan G A, et al. Carbidopa/levodopa for smoking cessation: a pilot study with negative results. Nicotine Tob Res 2000; 2: 71–78
   PubMedGoogle Scholar
• Epstein A M, King A C. Naltrexone attenuates acute cigarette smoking behaviour. Pharmacol Biochem Behav 2004; 77: 29–37
   PubMed Web of Science ®Google Scholar
• Krishnan-Sarin S, Meandzija B, O'Malley S. Naltrexone and nicotine patch smoking cessation: a preliminary study. Nicotine Tob Res 2003; 5: 851–857
   PubMed Web of Science ®Google Scholar
• Eissenberg T, Griffiths R R, Stitzer M L. Mecamylamine does not precipitate withdrawal in cigarette smokers. Psychopharmacology 1996; 127: 328–336
   PubMed Web of Science ®Google Scholar
• Harakas P, Foulds J. Acute effects of glucose tablets on craving, withdrawal symptoms and sustained attention in 12-h abstinent tobacco smokers. Psychopharmacology 2002; 161: 271–277
   PubMed Web of Science ®Google Scholar
• West R. Glucose therapy: role and efficacy. Paper presented at the Annual Meeting of the Italian Society of Pulmonary medicine. Rome November, 2000
   Google Scholar
• Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P. SR141716A, a central cannabinoid receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002; 13: 451–463
   PubMed Web of Science ®Google Scholar
• Cohen C, Kodas E, Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 2005; 81: 387–395
   PubMed Web of Science ®Google Scholar
• Van Gaal L F, Rissanen A M, Scheen A J, Ziegler O, Rossner S, for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1363–1364
   PubMedGoogle Scholar
• Coe J W, Brooks P R, Vetelino M G, et al. Varenicline (CP-526, 555): a novel, potent, and selective nicotinic receptor partial agonist for the treatment of smoking cessation: rationale, discovery, and mode of action. Presented at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco. Prague 2005
   Google Scholar
• Obach R S, Reed-Hagen A E, Krueger S S, et al. Metabolism and disposition of varenicline, a selective nicotinic receptor partial agonist, in humans and animals. Presented at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco. Prague March, 2005
   Google Scholar
• Oncken C, Watsky E, Reeves K, Anziano R. Varenicline is efficacious and well tolerated in promoting smoking cessation: results from a 7-week, randomized, placebo- and bupropion-controlled trial. Presented at the 11th Annual Meeting of the Society for Research on Nicotine and Tobacco. Prague March, 2005
   Google Scholar
• Lindmayer K, Horwith G, Fattom A, et al. Results of a phase I, double-blinded, controlled safety and immunogenicity trial of NICVAX, a conjugated nicotine vaccine. Abstract from the Society for Research on Nicotine and Tobacco Annual Meeting. 2003
   Google Scholar
• Bunce C. Safety, immunogenicity and some early signs of efficacy for the nicotine vaccine, TA-NIC. Paper presented at the UK National Smoking Cessation Conference. London 2005
   Google Scholar
• Lerman C, Kaufmann V, Rukstalis M, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med 2004; 140: 426–433
   PubMedGoogle Scholar
• West R, Hajek P, Nilsson F, Foulds J, May S, Meadows A. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology 2001; 153: 225–230
   PubMed Web of Science ®Google Scholar
• Lerman C, Niura R. Applying genetic approaches to the treatment of nicotine dependence. Oncogene 2002; 21: 7412–7420
   PubMed Web of Science ®Google Scholar
• Hurt R D, Croghan G A, Beede S D, Wolter T D, Croghan I T, Patten C A. Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels. Arch Pediatr Adolesc Med 2000; 154: 31–37
   PubMed Web of Science ®Google Scholar
• Oncken C A, Kranzler H R. Pharmacotherapies to enhance smoking cessation during pregnancy. Drug Alcohol Rev 2003; 22: 191–202
   PubMed Web of Science ®Google Scholar
• Williams J, Ziedonis D M, Foulds J. Nicotine nasal spray in the combination treatment of tobacco dependence in schizophrenia: a case series. Psychiatr Serv 2004; 55: 1064–1066
   PubMed Web of Science ®Google Scholar
• Baker A, Ivers R G, Bowman J, et al. Where there's smoke, there's fire: high prevalence of smoking among some sub-populations and recommendations for intervention. Drug Alcohol Rev 2006; 25: 85–96
   PubMed Web of Science ®Google Scholar
• Brookes S T, Whitely E, Egger M, Smith G D, Mulhearn P A, Peters T J. Sub-group analysis in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol 2004; 57: 229–236
   PubMed Web of Science ®Google Scholar
• Foulds J, Burke M, Perry E. Annual report of the tobacco dependence clinic at UMDNJ-School of Public Health: January–December 2002. 2003, Available at: www.tobaccoprogram.org/clinic-2.htm Accessed March 2005
   Google Scholar
• Steinberg M, Burke M, Richardson D, Perry E, Foulds J. Clinical implications of long-term pharmacotherapy for tobacco dependence. Paper presented at the annual conference of the Society for Research on Nicotine and Tobacco. New Orleans 2003
   Google Scholar
• Hatsukami D K, Slade J, Benowitz N L, et al. Reducing tobacco harm: research challenges and issues. Nicotine Tob Res 2002; 4(Suppl 2)S89–S101
   Google Scholar
• Hecht S S, Murphy S E, Carmella S G, et al. Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst 2004; 96: 107–115
   PubMedGoogle Scholar
• Godtfredsen N S, Osler M, Vestbo J, Andersen I, Prescott E. Smoking reduction, smoking cessation and incidence of fatal and non-fatal myocardial infarction in December 1976–98: a pooled cohort study. J Epidemiol Comm Health 2003; 57: 412–416
   PubMed Web of Science ®Google Scholar
• Fagerstrom K O, Tejding R, Westin A, Lunell E. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker?. Tob Control 1997; 6: 311–316
   PubMedGoogle Scholar
• Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction 2003; 98: 1395–1402
   PubMed Web of Science ®Google Scholar
• Borland R, Segan C J. The potential of quitlines to increase smoking cessation. Drug Alcohol Rev 2006; 25: 73–78
   PubMed Web of Science ®Google Scholar
• Etter J -F. The internet and the industrial revolution in smoking cessation counseling. Drug Alcohol Rev 2006; 25: 79–84
   PubMed Web of Science ®Google Scholar
• Baille A, Mattick R, Hall W, Webster P. Meta-analytic review of the efficacy of smoking cessation interventions. Drug Alcohol Review 1994; 13: 179–192
   PubMedGoogle Scholar
• Hughes J R. Combining behavioural therapy and pharmacotherapy for smoking cessation: an update, in integrating behavioural therapies with medications in the treatment of drug dependence. NIDA Research Monograph Series, no. 150, L S Onken, J D Blaine. US Department of Health and Human Services, Rockville, MD 1995, NIH Publications no. 95-3899
   Google Scholar
• American Psychiatric Association. Practice guideline for treatment of patients with nicotine dependence. American Psychiatric Association, Agency for Health Care Policy Reform (AHCPR), Washington, DC 1996
   Google Scholar
• McDonald H P, Garg A X, Haynes R B. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002; 288: 2868–2879
   PubMed Web of Science ®Google Scholar
• Zhu S, Melcer T, Sun J, Rosbrook B, Pierce J. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 2000; 18: 305–311
   PubMed Web of Science ®Google Scholar
• Thompson R S, McAfee T A, Stuart M E, Smith A E, Wilson J, Hendley M R. A review of clinical prevention services at Group Health Cooperative of Puget Sound. Am J Prev Med 1995; 11: 409–416
   PubMed Web of Science ®Google Scholar
• Schroeder S A. What to do with a patient who smokes. JAMA 2005; 294: 482–487
   PubMed Web of Science ®Google Scholar
• Ferguson J, Bauld L, Chesterman J, et al. The English smoking treatment services: one-year outcomes. Addiction 2005; 100(Suppl.2)59–69
   Google Scholar
• Fiore M C, McCarthy D E, Jackson T C, et al. Integrating smoking cessation treatment into primary care: an effectiveness study. Prev Med 2004; 38: 412–420
   PubMed Web of Science ®Google Scholar
• Lasser K, Boyd J W, Woolander S, Himmelstein D, McCormick D, Bor D H. Smoking and mental illness: a population-based prevalence study. JAMA 2000; 284: 2606–2610
   PubMed Web of Science ®Google Scholar
• Williams J, Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav 2004; 29: 1067–1083
   PubMed Web of Science ®Google Scholar
• Hall S M, Reus R F, Muñoz K L, et al. Nortriptyline and cognitive behavioural therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55: 683–690
   PubMed Web of Science ®Google Scholar
• Joseph A M, Willenbring M C, Nugent S M, Nelson D B. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. J Stud Alcohol 2004; 65: 681–691
   PubMed Web of Science ®Google Scholar
• Willhelm K, Niven H, Wedgwood L, Kay-Lambkin F. Smoking cessation and depression: current knowlrdge and future direction. Drug Alcohol Rev 2006; 25: 97–107
   PubMedGoogle Scholar